Impact of Incretin Therapy on Islet Dysfunction: An Underlying Defect in the Pathophysiology of Type 2 Diabetes

References

• . Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia. 2001;44(8):929–945
   PubMed Web of Science ®Google Scholar
• . Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104(6):787–794
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004;88(4):787–835
   PubMed Web of Science ®Google Scholar
• . Buchanan TA, Xiang AH, Peters RK, . Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51(9):2796–2803
   PubMed Web of Science ®Google Scholar
• . Young A. Inhibition of glucagon secretion. Adv Pharmacol. 2005; 52:151–171
   PubMedGoogle Scholar
• . Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev. 2007;28(3):253–283
   PubMed Web of Science ®Google Scholar
• . Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectrum. 2004;17(4):183–109
   Google Scholar
• . Moore CX, Cooper GJ. Co-secretion of amylin and insulin from cultured islet beta-cells: modulation by nutrient secretagogues, islet hormones and hypoglycemic agents. Biochem Biophys Res Commun. 1991;179(1):1–9
   PubMed Web of Science ®Google Scholar
• . Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–2157
   PubMed Web of Science ®Google Scholar
• . Bock G, Dalla Man C, Campioni M, . Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes. 2006;55(12):3536–3549
   PubMed Web of Science ®Google Scholar
• . Eriksson J, Franssila-Kallunki A, Ekstrand A, . Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med. 1989;321(6):337–343
   PubMed Web of Science ®Google Scholar
• . Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract. 1998;40( suppl): S21–S25
   Web of Science ®Google Scholar
• . Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102–110
   PubMed Web of Science ®Google Scholar
• . Bagust A, Beale S. Deteriorating beta-cell function in type 2 diabetes: a long-term model. QJM. 2003;96(4):281–288
   PubMed Web of Science ®Google Scholar
• . U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44(11):1249–1258
   PubMed Web of Science ®Google Scholar
• . Gerich JE, Schneider V, Dippe SE, . Characterization of the glucagon response to hypoglycemia in man. J Clin Endocrinol Metab. 1974;38(1):77–82
   PubMed Web of Science ®Google Scholar
• . Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 2004;53( suppl 3):S16–S21
   PubMed Web of Science ®Google Scholar
• . Hanson RL, Imperatore G, Narayan KM, . Family and genetic studies of indices of insulin sensitivity and insulin secretion in Pima Indians. Diabetes Metab Res Rev. 2001;17(4):296–303
   PubMed Web of Science ®Google Scholar
• . Henkin L, Bergman RN, Bowden DW, . Genetic epidemiology of insulin resistance and visceral adiposity. The IRAS Family Study design and methods. Ann Epidemiol. 2003;13(4):211–217
   PubMed Web of Science ®Google Scholar
• . Permutt MA, Wasson J, Cox N. Genetic epidemiology of diabetes. J Clin Invest. 2005;115(6):1431–1439
   PubMed Web of Science ®Google Scholar
• . Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122(7):481–486
   PubMed Web of Science ®Google Scholar
• . Field AE, Coakley EH, Must A, . Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med. 2001;161(13):1581–1586
   PubMedGoogle Scholar
• . Hart CL, Hole DJ, Lawlor DA, Davey Smith G. How many cases of Type 2 diabetes mellitus are due to being overweight in middle age? Evidence from the Midspan prospective cohort studies using mention of diabetes mellitus on hospital discharge or death records. Diabet Med. 2007;24(1):73–80
   PubMed Web of Science ®Google Scholar
• . Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world—-a growing challenge. N Engl J Med. 2007;356(3):213–215
   PubMed Web of Science ®Google Scholar
• . Narayan KM, Boyle JP, Thompson TJ, Gregg EW, Williamson DF. Effect of BMI on lifetime risk for diabetes in the U.S. Diabetes Care. 2007;30(6):1562–1566
   PubMed Web of Science ®Google Scholar
• . Wannamethee SG, Shaper AG, Walker M. Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes. J Epidemiol Community Health. 2005;59(2):134–139
   PubMed Web of Science ®Google Scholar
• . Fujimoto WY, Bergstrom RW, Boyko EJ, . Type 2 diabetes and the metabolic syndrome in Japanese Americans. Diabetes Res Clin Pract. 2000;50( suppl 2):S73–S76
   Web of Science ®Google Scholar
• . Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005–2012
   PubMed Web of Science ®Google Scholar
• . Bonora E. Protection of pancreatic beta-cells: is it feasible? Nutr Metab Cardiovasc Dis. 2008;18(1):74–83
   PubMed Web of Science ®Google Scholar
• . Ahrén B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care. 2005;28(8):1936–1940
   PubMed Web of Science ®Google Scholar
• . Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006; 29(12):2632–2637
   PubMed Web of Science ®Google Scholar
• . Balas B, Baig MR, Watson C, . The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92(4):1249–1255
   PubMed Web of Science ®Google Scholar
• . Bock T, Pakkenberg B, Buschard K. The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211. APMIS. 2003;111(12):1117–1124
   PubMed Web of Science ®Google Scholar
• . Bregenholt S, Møldrup A, Blume N, . The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun. 2005;330(2):577–584
   PubMed Web of Science ®Google Scholar
• . Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638–2643
   PubMed Web of Science ®Google Scholar
• . Chen J, Couto FM, Minn AH, Shalev A. Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun. 2006;346(3):1067–1074
   PubMed Web of Science ®Google Scholar
• . Degn KB, Juhl CB, Sturis J, . One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53(5):1187–1194
   PubMed Web of Science ®Google Scholar
• . Del Guerra S, Marselli L, Lupi R, . Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J Diabetes Complications. 2005;19(1):60–64
   PubMed Web of Science ®Google Scholar
• . Efanova IB, Zaitsev SV, Zhivotovsky B, . Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. J Biol Chem. 1998;273(50):33501–33507
   PubMed Web of Science ®Google Scholar
• . Finegood DT, McArthur MD, Kojwang D, . Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes. 2001;50(5):1021–1029
   PubMed Web of Science ®Google Scholar
• . Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res. 2002;34(9):504–508
   PubMed Web of Science ®Google Scholar
• . Gedulin BR, Nikoulina SE, Smith PA, . Exenatide (exendin-4) improves insulin sensitivity and (beta)-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology. 2005;146(4):2069–2076
   PubMed Web of Science ®Google Scholar
• . ; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial InvestigatorsGerstein HC, Yusuf S, Bosch J, Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368(9541):1096–1105
   PubMed Web of Science ®Google Scholar
• . Ishida H, Takizawa M, Ozawa S, . Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress. Metabolism. 2004;53(4):488–494
   PubMed Web of Science ®Google Scholar
• . Juhl CB, Hollingdal M, Sturis J, . Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes. 2002;51(2):424–429
   PubMed Web of Science ®Google Scholar
• . Kolterman OG, Buse JB, Fineman MS, . Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(7):3082–3089
   PubMed Web of Science ®Google Scholar
• . Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab. 2005;90(1):501–506
   PubMed Web of Science ®Google Scholar
• . Matthews D, Marre M, Le-Thi T, Zdravkovic M, Simo R. Liraglutide, a once-daily human GLP-1 analog, significantly improves β-cell function in subjects with type 2 diabetes. In: 68th Scientific Sessions of the American Diabetes Association; June 6–10, 2008; San Francisco, CA
   Google Scholar
• . Nyholm B, Orskov L, Hove KY, . The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism. 1999;48(7):935–941
   PubMed Web of Science ®Google Scholar
• . Rolin B, Larsen MO, Gotfredsen CF, . The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab. 2002;283(4):E745–E752
   PubMed Web of Science ®Google Scholar
• . Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE; Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis. 2001;12(5):413–423
   PubMed Web of Science ®Google Scholar
• . Sturis J, Gotfredsen CF, Rømer J, . GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol. 2003;140(1):123–132
   PubMed Web of Science ®Google Scholar
• . Tan MH, Baksi A, Krahulec B, ; GLAL Study Group. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care. 2005;28(3):544–550
   PubMed Web of Science ®Google Scholar
• . Utzschneider KM, Tong J, Montgomery B, . The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care. 2008;31(1):108–113
   PubMed Web of Science ®Google Scholar
• . Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med. 2004;21(6):568–576
   PubMed Web of Science ®Google Scholar
• . Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48(12):2270–2276
   PubMed Web of Science ®Google Scholar
• . Vilsbøll T, Brock B, Perrild H, . Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med. 2008;25(2):152–156
   PubMed Web of Science ®Google Scholar
• . Mu J, Woods J, Zhou YP, . Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006;55(6):1695–1704
   PubMed Web of Science ®Google Scholar
• . Mari A, Degn K, Brock B, Rungby J, Ferrannini E, Schmitz O. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care. 2007;30(8):2032–2033
   PubMed Web of Science ®Google Scholar
• . Actos® (pioglitazone hydrochloride tablets) [package insert]. Lincolnshire, IL and Indianapolis, IN: Takeda Pharmaceuticals America, Inc and Eli Lilly and Co; 2002. http://www.fda.gov/medwatch/SAFETY/2003/03Jan_labels/Actos_PI.pdf. March 2002.
   Google Scholar
• . Amaryl® (glimepiride tablets) [package insert]. Bridgewater, NJ: Aventis Pharmaceuticals Inc; 2005. http://www.fda.gov/medWatch/safety/2005/Nov_PI/Amaryl_PI.pdf. October 2005.
   Google Scholar
• . Avandia® (rosiglitazone) [package insert]. Boronia, Victoria: GlaxoSmithKline Australia Pty Ltd; 2008. http://www.gsk.com.au/resources.ashx/prescriptionmedicinesproductschilddataproinfo/515/FileName/1270CD65C97D606551EDBA1AEFA19F9C/PI_Avandia.pdf. October 2008.
   Google Scholar
• . Berria R, Gastaldelli M, Nauck M, Boldrin M, Asnaghi V, Balena R. Eight weeks treatment with R1583, a novel long-acting, human GLP-1 analogue improves beta cell function in metformin-treated diabetic subjects: a double-blind, placebo-controlled phase 2 study. In: 44th Annual Meeting of the EASD European Association for the Study of Diabetes; September 7–11, 2008; Rome, Italy
   Google Scholar
• . Byetta® (exenatide injection) [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2008. http://pi.lilly.com/us/byetta-pi.pdf. June 2008.
   Google Scholar
• . Galvus® (vildagliptin). Summary of Products Characteristics. Nuremberg, Germany: Novartis Pharma. http://www.emea.europa.eu/humandocs/PDFs/EPAR/galvus/H-771-PI-en.pdf
   Google Scholar
• . Garber A, Henry R, Ratner R, et al; for the LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial [published online ahead of print September 24, 2008]. Lancet.
   Google Scholar
• . Januvia™ (sitagliptin tablets) [package insert]. Whitehouse Station, NJ: Merck and Co, Inc; 2007. http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf
   Google Scholar
• . Kahn SE, Zinman B, Lachin JM, ; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008;31(5):845–851
   PubMed Web of Science ®Google Scholar
• . Micronase® (glyburide tablets) [package insert]. New York, NY: Pfizer, Inc; 2006. http://www.pfizer.com/files/products/uspi_micronase.pdf. June 2006.
   Google Scholar
• . Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol. 2008;588(2–3):325–332
   PubMed Web of Science ®Google Scholar
• . Nauck M, Frid A, Hermansen K, ; for the LEAD-2 Metformin Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met) [published online ahead of print October 17, 2008]. Diabetes Care.
   Google Scholar
• . Novo Nordisk. Liraglutide press release. http://press.novonordiskus.com/internal.aspx?rid=437. Updated October 17, 2008. Accessed December 12, 2008.
   Google Scholar
• . Symlin® (pramlintide acetate) injection [package insert]. Amylin Pharmaceuticals, Inc: San Diego, CA; 2008. https://www.symlin.com/pdf/SYMLIN-pi-combined.pdf. July 2008.
   Google Scholar
• . Werner U, Vandewalle B, Kerr Conte J, Pattou F, Pruniax M-P, Herling AW. The GLP-1 receptor agonist AVE0010 improves GSIS, prevents lipotoxicity-induced insulin depletion and preserves beta-cell function in human pancreatic islets. In: 68th Scientific Sessions of the American Diabetes Association; June 6–10, 2008; San Francisco, CA
   Google Scholar
• . Decker M, Hofflich H, Elias AN. Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis. Diabetes Obes Metab. 2008;10(8):617–625
   PubMed Web of Science ®Google Scholar
• . Dormandy JA, Charbonnel B, Eckland DJ, ; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–1289
   PubMed Web of Science ®Google Scholar
• . Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf. 2007;30(12):1127–1142
   PubMed Web of Science ®Google Scholar
• . Kahn SE, Haffner SM, Heise MA, ; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443
   PubMed Web of Science ®Google Scholar
• . Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194–206
   PubMed Web of Science ®Google Scholar
• . Avandia® (rosiglitazone maleate) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2008
   Google Scholar
• . Deacon CF, Holst JJ. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes. Int J Biochem Cell Biol. 2006;38(5–6):831–844
   PubMed Web of Science ®Google Scholar
• . Holst JJ, Deacon CF. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr Opin Pharmacol. 2004;4(6):589–596
   PubMed Web of Science ®Google Scholar
• . Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest. 1988;81(2):442–448
   PubMed Web of Science ®Google Scholar
• . Cherrington AD, Sindelar D, Edgerton D, Steiner K, McGuinness OP. Physiological consequences of phasic insulin release in the normal animal. Diabetes. 2002;51( suppl 1):S103–S108
   Web of Science ®Google Scholar
• . Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest. 2000;106(3):329–333
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91(1):301–307
   PubMed Web of Science ®Google Scholar
• . Pratley R. Islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. Endocrinol Metab Clin North Am. 2006;35( suppl 1):6–11
   PubMed Web of Science ®Google Scholar
• . Lugari R, Dei Cas A, Ugolotti D, . Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes. Horm Metab Res. 2002;34(3):150–154
   PubMed Web of Science ®Google Scholar
• . Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50(3):609–613
   PubMed Web of Science ®Google Scholar
• . Robertson RP, Harmon J, Tran PO, Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes. 2004;53( suppl 1):S119–S124
   PubMed Web of Science ®Google Scholar
• . Biarnés M, Montolio M, Nacher V, Raurell M, Soler J, Montanya E. Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes. 2002;51(1):66–72
   PubMed Web of Science ®Google Scholar
• . Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89(2):463–478
   PubMed Web of Science ®Google Scholar
• . Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A. 1987;84(23):8628–8632
   PubMed Web of Science ®Google Scholar
• . Mather KJ, Paradisi G, Leaming R, . Role of amylin in insulin secretion and action in humans: antagonist studies across the spectrum of insulin sensitivity. Diabetes Metab Res Rev. 2002;18(2):118–126
   PubMed Web of Science ®Google Scholar
• . Kahn SE. The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med. 2000;108( suppl 6a):2S–8S
   Google Scholar
• . Maruyama H, Hisatomi A, Orci L, Grodsky GM, Unger RH. Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest. 1984;74(6):2296–2299
   PubMed Web of Science ®Google Scholar
• . Müller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med. 1970;283(3):109–115
   PubMed Web of Science ®Google Scholar
• . Lefebvre PJ. Alpha-cell function in type 2 diabetes. Eur Endocrin Dis. 2006;41–42
   Google Scholar
• . Rahier J, Goebbels RM, Henquin JC. Cellular composition of the human diabetic pancreas. Diabetologia. 1983;24(5):366–371
   PubMed Web of Science ®Google Scholar
• . Göke B. Islet cell function: alpha and beta cells—partners towards normoglycaemia. Int J Clin Pract Suppl. 2008;(159):2–7
   Google Scholar
• . Knudsen LB, Nielsen PF, Huusfeldt PO, . Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43(9): 1664–1669
   PubMed Web of Science ®Google Scholar
• . Meier JJ. Beta cell mass in diabetes: a realistic therapeutic target? Diabetologia. 2008;51(5):703–713
   PubMed Web of Science ®Google Scholar
• . Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006;29(5):1130–1139
   PubMed Web of Science ®Google Scholar
• . Festa A, Williams K, Hanley AJ, Haffner SM. Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes. Comparison of surrogate markers with first phase insulin secretion from an intravenous glucose tolerance test. Diabetes. 2008;57(6):1638–1644
   PubMed Web of Science ®Google Scholar
• . The DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care. 1988;11(7):567–573
   PubMed Web of Science ®Google Scholar
• . Nikolaidis LA, Mankad S, Sokos GG, . Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109(8):962–965
   PubMed Web of Science ®Google Scholar
• . Nikolaidis LA, Doverspike A, Hentosz T, . Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther. 2005;312(1):303–308
   PubMed Web of Science ®Google Scholar
• . Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214(3): 829–835
   PubMedGoogle Scholar
• . Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628–2635
   PubMed Web of Science ®Google Scholar
• . Buse JB, Klonoff DC, Nielsen LL, . Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007;29(1):139–153
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092–1100
   PubMed Web of Science ®Google Scholar
• . Kendall DM, Riddle MC, Rosenstock J, . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083–1091
   PubMed Web of Science ®Google Scholar
• . Kim D, MacConell L, Zhuang D, . Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30(6):1487–1493
   PubMed Web of Science ®Google Scholar
• . Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211–1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004;27(6):1335–1342
   PubMed Web of Science ®Google Scholar
• . Vilsbøll T, Zdravkovic M, Le-Thi T, . Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1608–1610
   PubMed Web of Science ®Google Scholar
• . Gutzwiller JP, Drewe J, Göke B, . Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999;276(5 pt 2):R1541–R1544
   Web of Science ®Google Scholar
• . Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117(2):77–88
   PubMedGoogle Scholar
• . Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care. 2001;24(2):371–381
   PubMed Web of Science ®Google Scholar
• . Russell-Jones D, Vaag A, Schmitz O, . Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: all as add-on to metformin and a sulfonylurea in type 2 diabetes. Diabetes. 2008;57( suppl 1):A159–A160
   Web of Science ®Google Scholar
• . Marre M, Shaw J, Brandle M, . Liraglutide, a once-daily human GLP-1 analog, added to a sulfonylurea (SU) offers significantly better glycemic control and favorable weight change compared with rosiglitazone and SU combination therapy in subjects with type 2 diabetes. In: 68th Scientific Sessions of the American Diabetes Association (ADA); June 6–10, 2008; San Francisco, CA
   Google Scholar
• . Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267(11):7402–7405
   PubMed Web of Science ®Google Scholar
• . Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153–165
   PubMed Web of Science ®Google Scholar
• . Byetta® [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2007
   Google Scholar
• . Mari A, Nielsen LL, Nanayakkara N, DeFronzo RA, Ferrannini E, Halseth A. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. Horm Metab Res. 2006;38(12):838–844
   PubMed Web of Science ®Google Scholar
• . Ghofaili KA, Fung M, Ao Z, . Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation. 2007;83(1):24–28
   PubMed Web of Science ®Google Scholar
• . Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45(2):195–202
   PubMed Web of Science ®Google Scholar
• . Chang AM, Jakobsen G, Sturis J, . The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes. 2003;52(7):1786–1791
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Frid A, Hermansen K, . Liraglutide, a once-daily human glucagon-like peptide-1 analog, in type 2 diabetes provides similar glycemic control with reduced body weight compared with glimepiride when added to metformin. In: 68th Scientific Sessions of the American Diabetes Association (ADA); June 6–10, 2008; San Francisco, CA
   Google Scholar
• . Zinman B, Gerich J, Buse J, . Effect of the GLP-1 analogue liraglutide on glycaemic control and weight reduction in patients on metformin and rosiglitazone: a randomised double-blind placebo-controlled trial. In: 44th Annual Meeting of the European Association for the Study of Diabetes (EASD); September 7–11, 2008; Rome, Italy
   Google Scholar
• . Blonde L, Rosenstock J, Sesti G, . Liraglutide: superior glycemic control vs exenatide when added to metformin and/or SU in type 2 diabetes. In: Canadian Diabetes Association (CDA)/Canadian Society of Endocrinology and Metabolism (CSEM) Professional Conference and Annual Meeting; October 15–18, 2008; Montreal, Quebec, Canada
   Google Scholar
• . Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9(2):186–193
   PubMed Web of Science ®Google Scholar
• . Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabet Med. 2007;24(9):955–961
   PubMed Web of Science ®Google Scholar
• . Mari A, Scherbaum WA, Nilsson PM, . Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab. 2008;93(1):103–109
   PubMed Web of Science ®Google Scholar
• . Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia. 2003;46(1):3–19
   PubMed Web of Science ®Google Scholar
• . Franklin I, Gromada J, Gjinovci A, Theander S, Wollheim CB. Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes. 2005;54(6):1808–1815
   PubMed Web of Science ®Google Scholar